Trial Profile
Effects of pemetrexed plus cisplatin on S100A9-myeloid derived suppressor cells versus docetaxel plus cisplatin in patients with non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Apr 2016
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Cisplatin; Docetaxel
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Pharmacodynamics
- 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research
- 15 Apr 2016 New trial record